Gemtuzumab ozogamicin

Gemtuzumab ozogamicin
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD33
Clinical data
Trade names	Mylotarg
AHFS/Drugs.com	Monograph
MedlinePlus	a618005
License data	US DailyMed: Gemtuzumab_ozogamicin;
Pregnancy; category	AU: D;
Routes of; administration	Intravenous
ATC code	L01FX02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	220578-59-6 ;
DrugBank	DB00056 ;
ChemSpider	none;
UNII	8GZG754X6M;
KEGG	D03259 ;
ChEMBL	ChEMBL1201506 ;
Chemical and physical data
Molar mass	151500 g·mol−1
	(what is this?) (verify)

Gemtuzumab ozogamicin, sold under the brand name Mylotarg, is an antibody-drug conjugate (a drug-linked monoclonal antibody) that is used to treat acute myeloid leukemia (AML).

The most common side effects include infection, febrile neutropenia, decreased appetite, hyperglycemia, mucositis, hypoxia, hemorrhage, increased transaminase, diarrhea, nausea, and hypotension. However, the addition of gemtuzumab ozogamicin to standard chemotherapy regimens does not increase infection rates.